Cell-based immunotherapies in gynecologic cancers

Purpose of review This review provides an update on recent developments in cell-based immunotherapy in gynecologic cancers. Recent findings Chimeric antigen receptor (CAR) technology has made significant progress allowing now for not only expressing CARs on T-cells, but also on other immune effector cells, such as natural killer cells and macrophages. Cell-based vaccines have started to show promising results in clinical trials. Summary Cell-based immunotherapies in gynecologic cancers continue to evolve with promising clinical efficacy in select patients.